Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?

Could Help Patients Who Lack Own Antibody Response

 
• By Andrew McConaghie

Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization. 

Covid test
Serology tests found around 40% of trial patients had generated no antibodies against the disease - making them higher risk, and more likely to benefit from REGN-COV2.

More from Archive

More from Scrip